I am an Assistant Professor in the Hepatology Group in the NIHR Nottingham Biomedical Research Centre and the MRC-funded Nottingham Molecular Pathology Node (http://www.nmpn.info/). My research includes translational research projects in the following areas:
- Drug-induced liver injury (assessment, genetic and environmental factors that affect drug metabolism and hepatotoxicity).
- Non-alcoholic fatty liver disease and alcoholic liver disease (mechanisms and biomarkers of liver injury).
- Genetic determinants of liver disease.
- Development and validation of markers of oxidative stress in the evaluation of acute liver injury and chronic liver diseases.
- Non-invasive assessment of liver fibrosis.
- Clinical application of liver biomarkers.
- Experimental diagnostics of chronic liver injury.
I am Divisional Safety Officer and Human Tissue Authority Person Designate for the Nottingham Digestive Diseases Centre.
I am a member of the UK Stratified Medicine and Pharmacogenetics Committee and am involved in developing Biobank networks.
Analysis of genetic determinants of the development of alcoholic liver disease. (Newcastle University)
Improvement of E. coli nitroreductase by mutagenesis: a route to optimization of virus- directed enzyme-prodrug cancer therapy. (Cobra Therapeutics)
DNA double-strand break repair in E. coli. (Nottingham University)
Role of novel Type IV secretion systems in Helicobacter pylori virulence. (Nottingham University)
Degree: Molecular Biology and Biochemistry (Durham University)
PhD: Escherichia coli genes essential for formate-dependent nitrite reduction, cytochrome c biosynthesis and periplasmic nitrate reduction. (Birmingham University)
Quantification of circulating biomarkers including Luminex multiplex analysis on Bioplex 200
Characterisation and phenotyping of patient cohorts and analysis of clinical data
Expression analyses including assessment of liver tissue markers
Molecular genetics including detection of polymorphisms, cloning, PCR and sequencing
Biochemistry (including protein expression, purification and analysis)
Biobanking: setting up a Research Tissue Bank, clinical sample collection, storage and cataloging/databases
Microbiology: specialist in E.coli and H.pylori manipulation and phenotyping
I am a postdoctoral research scientist in the Hepatology Group in the NIHR Nottingham Digestive Diseases Biomedical Research Unit and Nottingham Molecular Pathology Node. I am involved in… read more
NICOLETTI P, AITHAL GP, BJORNSSON ES, ANDRADE RJ, SAWLE A, ARRESE M, BARNHART HX, BONDON-GUITTON E, HAYASHI PH, BESSONE F, CARVAJAL A, CASCORBI I, CIRULLI ET, CHALASANI N, CONFORTI A, COULTHARD SA, DALY MJ, DAY CP, DILLON JF, FONTANA RJ, GROVE JI, HALLBERG P, HERNÁNDEZ N, IBÁÑEZ L, KULLAK-UBLICK GA, LAITINEN T, LARREY D, LUCENA MI, MAITLAND-VAN DER ZEE AH, MARTIN JH, MOLOKHIA M, PIRMOHAMED M, POWELL EE, QIN S, SERRANO J, STEPHENS C, STOLZ A, WADELIUS M, WATKINS PB, FLORATOS A, SHEN Y, NELSON MR, URBAN TJ, DALY AK and , 2017. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology. 152, 1078-1089 GROVE JI, AUSTIN M, TRIBBLE J, AITHAL GP and VERMA S, 2016. Monozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms? Annals of Hepatology. 15(2)(Mar-Apr), 277-82
GROVE JI and AITHAL GP, 2015. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert opinion on drug metabolism & toxicology. 11, 395-409
I am a postdoctoral research scientist in the Hepatology Group in the NIHR Nottingham Digestive Diseases Biomedical Research Unit and Nottingham Molecular Pathology Node. I am involved in translational research in the following areas: Drug-induced liver injury (assessment, genetic and environmental factors that affect drug metabolism and hepatotoxicity). Non-alcoholic fatty liver disease (mechanisms and biomarkers of liver injury). Hepatobiliary imaging (assessment of degree of liver injury). Development and validation of markers of oxidative stress in the evaluation of acute liver injury and chronic liver diseases. Non-invasive assessment of liver fibrosis. Experimental diagnostics of chronic liver injury. Clinical application of liver biomarkers.
Identification of serum biomarkers of non-alcoholic fatty liver disease (NAFLD)
Investigation of microbiome signatures associated with chronic liver disease: a target for interventions and tool for disease monitoring.
Investigation of the role of genetic polymorphisms in contributing to NAFLD development and progression.
Association of HLA types with drug-induced liver injury and assessment of injury phenotypes.
Investigation of serum biomarkers in alcoholic liver disease.
I am the coordinator of a European Biorepository for drug-induced liver injury (Pro-Euro DILI).
I also completed a NUH pump-priming award to investigate telomerase activity as a measure of cumulative burden of oxidative stress in non-alcoholic fatty liver disease.
Role of novel Type IV secretion systems in Helicobacter pylori virulence. (PI Rob Delahay)
DNA double-strand break repair in E. coli. (PI Bob Lloyd)
The Nottingham Molecular Pathology Node for Integrated Multi-platform Biomarker Research and Knowledge Transfer -bringing together informatics, computational modeling and molecular pathology to find new biomarkers for a range of diseases, particularly those affecting the digestive and respiratory systems and the liver.